For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Vaxcyte Inc’s stock clocked out at $34.46, down -2.77% from its previous closing price of $35.44. In other words, the price has decreased by -$2.77 from its previous closing price. On the day, 1.21 million shares were traded.
Ratios:
To gain a deeper understanding of PCVX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 17.70 and its Current Ratio is at 17.70. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On December 20, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $135.
On December 07, 2023, Mizuho started tracking the stock assigning a Buy rating and target price of $69.Mizuho initiated its Buy rating on December 07, 2023, with a $69 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’25 when Eydelman Mikhail sold 5,000 shares for $70.74 per share. The transaction valued at 353,699 led to the insider holds 41,620 shares of the business.
Eydelman Mikhail bought 5,000 shares of PCVX for $344,350 on Mar 05 ’25. On Mar 03 ’25, another insider, Wassil Jim, who serves as the CHIEF OPERATING OFFICER of the company, sold 8,000 shares for $73.27 each. As a result, the insider received 586,165 and left with 154,931 shares of the company.
Stock Price History:
Over the past 52 weeks, PCVX has reached a high of $121.06, while it has fallen to a 52-week low of $27.66. The 50-Day Moving Average of the stock is 5.51%, while the 200-Day Moving Average is calculated to be -55.51%.
Shares Statistics:
A total of 128.94M shares are outstanding, with a floating share count of 125.07M. Insiders hold about 3.05% of the company’s shares, while institutions hold 113.76% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 5.0 analysts. The consensus estimate for the next quarter is -$1.21, with high estimates of -$1.04 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$4.11 and -$5.09 for the fiscal current year, implying an average EPS of -$4.69. EPS for the following year is -$5.21, with 5.0 analysts recommending between -$4.04 and -$5.68.
